|  | 100% positive assessments 1 | 0–49% positive assessments 2 | ||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Prev.(%) | PR | Adj. PR | 95% CI | Prev.(%) | PR | Adj. PR | 95% CI |
Gender | |||||||||
(N = 25377) | Female | 61.2 | 1 | 13 | Â | 19.4 | 1 | 1 | Â |
 | Male | 61.2 | 1.00 | 0.95 | 0.93 – 0.97 | 19.2 | 0.99 | 1.06 | 1.00 – 1.13 |
Age (years) | |||||||||
(N = 25377) | 18–24 | 47.8 | 1 | 13 |  | 26.2 | 1 | 1 |  |
 | 25–29 | 52.3 | 1.09 | 1.07 | 0.99 – 1.16 | 23.2 | 1.03 | 0.92 | 0.82 – 1.04 |
 | 30–34 | 56.8 | 1.19 | 1.18 | 1.10 – 1.26 | 21.6 | 1.00 | 0.84 | 0.75 – 0.93 |
 | 35–39 | 56.3 | 1.18 | 1.20 | 1.13 – 1.29 | 21.8 | 1.01 | 0.79 | 0.71 – 0.88 |
 | 40–44 | 57.7 | 1.21 | 1.29 | 1.19 – 1.38 | 20.9 | 1.00 | 0.71 | 0.63 – 0.79 |
 | 45–49 | 57.5 | 1.20 | 1.31 | 1.22 – 1.41 | 21.9 | 0.90 | 0.70 | 0.62 – 0.78 |
 | 50–54 | 61.1 | 1.28 | 1.44 | 1.33 – 1.55 | 19.0 | 0.88 | 0.57 | 0.50 – 0.65 |
 | 55–59 | 64.5 | 1.35 | 1.55 | 1.43 – 1.66 | 17.9 | 0.74 | 0.52 | 0.46 – 0.60 |
 | 60–64 | 67.1 | 1.40 | 1.61 | 1.50 – 1.73 | 15.6 | 0.67 | 0.45 | 0.40 – 0.52 |
 | 65–69 | 73.0 | 1.53 | 1.76 | 1.64 – 1.88 | 13.1 | 0.58 | 0.38 | 0.33 – 0.45 |
 | 70–74 | 71.4 | 1.49 | 1.73 | 1.61 – 1.86 | 14.9 | 0.53 | 0.43 | 0.38 – 0.50 |
 | 75–79 | 70.1 | 1.47 | 1.73 | 1.61 – 1.85 | 14.8 | 0.51 | 0.42 | 0.36 – 0.48 |
 | 80+ | 69.8 | 1.46 | 1.73 | 1.60 – 1.87 | 15.6 | 0.57 | 0.42 | 0.36 – 0.50 |
Further education (years) | |||||||||
(N = 24220) | None | 60.2 | 1 | 13 | Â | 19.6 | 1 | 1 | Â |
 | Less than 2 | 60.4 | 1.01 | 1.03 | 0.99 – 1.07 | 20.8 | 1.06 | 1.04 | 0.94 – 1.16 |
 | 2–4 | 61.5 | 0.91 | 1.02 | 0.99 – 1.05 | 19.1 | 0.97 | 1.02 | 0.95 – 1.10 |
 | 5 or more | 61.2 | 0.80 | 1.00 | 0.97 – 1.04 | 18.8 | 0.96 | 1.03 | 0.93 – 1.14 |
 | Undergoing education or other | 61.4 | 0.90 | 1.07 | 1.02 – 1.12 | 17.3 | 0.88 | 0.85 | 0.74 – 0.97 |
Frequency of attendance (times per year) | |||||||||
(N = 25377) | 0–1 | 64.2 | 1 | 13 |  | 19.0 | 1 | 1 |  |
 | 2–3 | 60.9 | 0.95 | 0.98 | 0.95 – 1.01 | 19.2 | 1.01 | 0.96 | 0.88 – 1.05 |
 | 4–5 | 61.9 | 0.96 | 1.01 | 0.98 – 1.05 | 19.3 | 1.02 | 0.92 | 0.84 – 1.01 |
 | 6–7 | 60.0 | 0.94 | 1.01 | 0.98 – 1.06 | 19.3 | 1.02 | 0.85 | 0.77 – 0.94 |
 | 8–9 | 60.6 | 0.94 | 1.04 | 1.00 – 1.09 | 19.5 | 1.03 | 0.82 | 0.73 – 0.92 |
 | 10+ | 60.1 | 0.94 | 1.09 | 1.04 – 1.14 | 19.8 | 1.04 | 0.74 | 0.67 – 0.83 |
Duration of listing (years) | |||||||||
(N = 16880) | Less than 1 | 60.5 | 1 | 13 | Â | 20.3 | 1 | 1 | Â |
 | 1–2 | 62.7 | 1.04 | 1.01 | 0.96 – 1.07 | 18.4 | 0.91 | 0.99 | 0.86 – 1.12 |
 | 3–7 | 61.2 | 1.01 | 0.96 | 0.91 – 1.01 | 19.0 | 0.93 | 1.05 | 0.93 – 1.18 |
 | 8–12 | 62.4 | 1.03 | 0.96 | 0.90 – 1.01 | 19.1 | 0.94 | 1.11 | 0.98 – 1.27 |
 | 13+ | 65.8 | 1.09 | 1.00 | 0.94 – 1.06 | 16.0 | 0.79 | 0.94 | 0.83 – 1.08 |
Self-rated health | |||||||||
(N = 25377) | Excellent | 71.8 | 1 | 13 | Â | 13.4 | 1 | 1 | Â |
 | Very good | 64.8 | 0.90 | 0.86 | 0.83 – 0.89 | 15.7 | 1.17 | 1.27 | 1.14 – 1.43 |
 | Good | 61.1 | 0.85 | 0.72 | 0.70 – 0.75 | 19.2 | 1.43 | 1.90 | 1.69 – 2.13 |
 | Fair | 52.4 | 0.73 | 0.59 | 0.56 – 0.61 | 26.5 | 1.97 | 2.94 | 2.60 – 3.31 |
 | Poor | 48.2 | 0.67 | 0.53 | 0.49 – 0.58 | 30.2 | 2.25 | 3.43 | 2.96 – 3.97 |
Chronic condition | |||||||||
(N = 25017) | No | 64.6 | 1 | 13 | Â | 18.6 | 1 | 1 | Â |
 | Yes-KRTC | 67.9 | 1.10 | 1.09 | 1.06 – 1.12 | 15.9 | 0.86 | 0.84 | 0.77 – 0.92 |
 | Yes-other or multiple | 57.1 | 0.93 | 1.01 | 0.98 – 1.04 | 22.2 | 1.19 | 0.96 | 0.90 – 1.02 |
Chronic condition | |||||||||
(N = 17058) | Â | 61.6 | 1 | 13 | Â | 18.6 | 1 | 1 | Â |
 | K – Cardiovascular | 70.6 | 1.15 | 1.12 | 1.08 – 1.16 | 13.7 | 0.73 | 0.76 | 0.67 – 0.87 |
 | R – Respiratory | 60.6 | 0.98 | 1.05 | 0.99 – 1.10 | 19.4 | 1.04 | 0.90 | 0.79 – 1.04 |
 | T – Endocrine | 68.2 | 1.11 | 1.11 | 1.06 – 1.16 | 17.9 | 0.96 | 0.94 | 0.81 – 1.08 |
 | C – Cancer | 75.2 | 1.22 | 1.28 | 1.19 – 1.37 | 11.7 | 0.63 | 0.55 | 0.39 – 0.77 |